These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 9679894)

  • 1. Diagnosis and staging of prostate cancer.
    Flanigan RC
    J Urol; 1998 Aug; 160(2):443-4. PubMed ID: 9679894
    [No Abstract]   [Full Text] [Related]  

  • 2. [PSA 2010--the beginning of a new era in early detection of prostate cancer].
    Börgermann C; Sieverding M; Fornara P; Graefen M; Hammerer P; Semjonow A; Schröder F; Rübben H
    Urologe A; 2006 Sep; 45 Suppl 4():127-33. PubMed ID: 16941115
    [No Abstract]   [Full Text] [Related]  

  • 3. Prostate specific antigen density: a method for differentiating prostate carcinoma from benign prostatic hypertrophy demonstrates ethnic variation.
    Martin AA; Clejan S
    J La State Med Soc; 1994 Apr; 146(4):163-71. PubMed ID: 7516401
    [No Abstract]   [Full Text] [Related]  

  • 4. [Conceptual and technical issues in pathologic diagnosis of prostate cancer].
    Jiang ZM; Zhang HZ; Zheng L
    Zhonghua Bing Li Xue Za Zhi; 2009 Jul; 38(7):433-5. PubMed ID: 19781187
    [No Abstract]   [Full Text] [Related]  

  • 5. [Prostate cancer histoseminar: Update of the 2016 WHO classification - case No. 8: Acinar prostatic adenocarcinoma, Gleason score 6 (3+3)].
    Ferlicot S
    Ann Pathol; 2017 Jun; 37(3):259-263. PubMed ID: 28522121
    [No Abstract]   [Full Text] [Related]  

  • 6. [The role of imaging in the diagnosis and staging of cancer of the prostate].
    Dana A
    J Radiol; 1999 Jun; 80(6):609. PubMed ID: 10417901
    [No Abstract]   [Full Text] [Related]  

  • 7. Prostate-specific antigen in tissue from fine-needle aspiration biopsies.
    Pousette A; Carlström K; Tribukait B; Grande M; Engström AH; Henriksson P; Stege R
    Br J Urol; 1997 Mar; 79 Suppl 1():104-6. PubMed ID: 9088282
    [No Abstract]   [Full Text] [Related]  

  • 8. Racial variations in the performance of prostate specific antigen and prostate specific antigen density in the era of extended prostate biopsy schemes.
    Elliott CS; Shinghal R; Presti JC
    J Urol; 2008 Oct; 180(4):1318-23; discussion 1323-4. PubMed ID: 18707710
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostate specific antigen and pathological features of prostate cancer in black and white patients: a comparative study based on radical prostatectomy specimens.
    Pettaway CA; Troncoso P; Ramirez EI; Johnston DA; Steelhammer L; Babaian RJ
    J Urol; 1998 Aug; 160(2):437-42. PubMed ID: 9679893
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial.
    Catalona WJ; Partin AW; Slawin KM; Naughton CK; Brawer MK; Flanigan RC; Richie JP; Patel A; Walsh PC; Scardino PT; Lange PH; deKernion JB; Southwick PC; Loveland KG; Parson RE; Gasior GH
    Urology; 2000 Mar; 55(3):372-6. PubMed ID: 10699613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gleason score from needle biopsy of the prostate predicts that from radical prostatectomy in most cases.
    Yu DS
    J Chin Med Assoc; 2005 Apr; 68(4):162. PubMed ID: 15850064
    [No Abstract]   [Full Text] [Related]  

  • 12. Unusual and potentially important finding in a prostatic needle biopsy.
    Pai SA; Katti SV
    J Clin Pathol; 2021 Jan; 74(1):e1. PubMed ID: 32467318
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Use of lower prostate specific antigen cutoffs for prostate cancer screening in black and white men.
    Ansong KS
    J Urol; 1999 May; 161(5):1585. PubMed ID: 10210419
    [No Abstract]   [Full Text] [Related]  

  • 14. Relationships between prostate-specific antigen and prostate volume in black and white men with benign prostate biopsies.
    Fowler JE; Bigler SA; Kilambi NK; Land SA
    Urology; 1999 Jun; 53(6):1175-8. PubMed ID: 10367848
    [TBL] [Abstract][Full Text] [Related]  

  • 15. It's time to abandon an upper limit of normal for prostate specific antigen: assessing the risk of prostate cancer.
    Thompson IM; Ankerst DP; Etzioni R; Wang T
    J Urol; 2008 Oct; 180(4):1219-22. PubMed ID: 18707707
    [No Abstract]   [Full Text] [Related]  

  • 16. Can we accurately identify men with low risk prostate cancer?
    Neal DE
    J Urol; 2008 Oct; 180(4):1217-8. PubMed ID: 18707718
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of prostate-specific antigen screening during the last decade: development of clinicopathological variables independently of the biopsy core number.
    Ploussard G; Azancot V; Nicolaiew N; Xylinas E; Salomon L; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    BJU Int; 2010 Nov; 106(9):1293-7. PubMed ID: 20456338
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Imaging procedures to diagnose prostate cancer].
    Seitz M; Scher B; Scherr M; Tilki D; Schlenker B; Gratzke C; Schipf A; Stanislaus P; Müller-Lisse U; Reich O; Stief C
    Urologe A; 2007 Oct; 46(10):W1435-46; quiz W1447-8. PubMed ID: 17665166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Percent free prostate-specific antigen for first-time prostate biopsy.
    Lee CT; Scardino PT
    Urology; 2001 Apr; 57(4):594-8. PubMed ID: 11306355
    [No Abstract]   [Full Text] [Related]  

  • 20. Re: The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
    Roach M
    J Urol; 1993 Dec; 150(6):1923-4. PubMed ID: 7693984
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.